Travere Therapeutics Inc. (NASDAQ: TVTX) entered into an exclusive licensing agreement with Everest Medicines for civorebrutinib, an investigational oral BTK inhibitor for rare kidney diseases in markets outside China and certain East and Southeast Asian countries.

Under the agreement, Everest will receive an upfront payment of $112.5 million and is eligible for up to approximately $1.03 billion in additional milestone payments across up to five indications. Travere will pay tiered royalties on future sales ranging from high single-digit to double-digit percentages based on annual net sales thresholds.

Civorebrutinib is a covalent reversible Bruton's tyrosine kinase inhibitor designed for immune-mediated kidney diseases. The drug demonstrated proof of concept in a Phase 1/2 clinical trial for primary membranous nephropathy, showing rapid and sustained reductions in anti-PLA2R autoantibodies and proteinuria with high rates of immunologic and clinical remission through 52 weeks of follow-up.

Travere plans to investigate civorebrutinib in primary membranous nephropathy, immune-mediated focal segmental glomerulosclerosis and minimal change disease. BTK plays a role in B-cell activation, which contributes to kidney injury in immune-mediated kidney diseases through B-cell activation and autoantibody production.

The license agreement becomes effective upon satisfaction of customary conditions, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

Travere will host a conference call on June 2, 2026, at 8:30 a.m. ET to discuss the agreement. The information is based on a company press release.